Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Pharnext SCA
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharnext SCA
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pharnext SCA
OTC:PNEXF
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other Long-Term Assets
€16.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Other Long-Term Assets
€2.4m
CAGR 3-Years
-11%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other Long-Term Assets
€7m
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
23%
OSE Immunotherapeutics SA
PAR:OSE
Other Long-Term Assets
€194k
CAGR 3-Years
6%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Pharnext SCA
Glance View

Market Cap
6T USD
Industry
Biotechnology

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

PNEXF Intrinsic Value
Not Available

See Also

Back to Top